The Clinical Research Unit (CRU) conducts clinical trials, with a focus on hematology/oncology, and receives patients from both McGill-affiliated hospitals and hospitals throughout Québec. The CRU has an established track record in novel cancer therapeutics, concentrating on Phase I and early Phase II development. The CRU has expertise in pharmacokinetic and pharmacodynamic studies, with the ability to prepare patient samples for molecular analyses in McGill and in outside laboratories.
Closely tied to the Lady Davis Institute for Medical Research and the MCTRC, the Unit provides the opportunity for translational medical research, linking innovative work at the laboratory bench to clinical experience at the bedside. The CRU plays an essential role in the mission of the MCTRC to bring cancer research from basic science laboratories into the cancer clinic.
The CRU is furnished with state-of-the-art equipment, including a dedicated four-bed patient area, an additional single patient room and an adjacent nursing station for the continuous monitoring of patients. Patient treatment, follow-up and care take place in the clinic, with 24-hour nursing if necessary.
Investigations carried out in the CRU are approved and monitored by the Research Ethics Office of the Jewish General Hospital and the McGill Institutional Review Board. Policies and procedures are in place to adhere to the legislation of Health Canada and the US Food and Drug Administration; preparation for study activation is highly efficient. The CRU has undergone a number of rigorous external audits, always achieving outstanding evaluations. To learn more about the CRU, please visit their page in the Jewish General Hospital.
Director: Wilson Miller, MD, PhD
Associate Director: Sarit Assouline, MD
Program Coordinator: Adele Cascini, BA
Nurse Manager: Vida Stibernik, RN, BScN
Ms. Adele Cascini, Program Coordinator
Tel.: (514) 340 8222 ext. 23951
acascini [at] jgh.mcgill.ca (Email)